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Abstract 
 
Background: Driving cessation is associated with poor health-related outcomes. People with chronic 
diseases are often prescribed long-term opioid agonists that have the potential to impair driving. 
Studies evaluating the impact of opioids on driving-related psychomotor skills report contradictory 
results likely due to heterogeneous designs, assessment tools and study populations. A better 
understanding of the effects of regular therapeutic opioid agonists on driving can help to inform the 
balance between individuals’ independence and community safety.  
 
Aim: To identify the literature assessing the impact of regular therapeutic opioid agonists on driving-
related psychomotor skills for people with chronic pain or chronic breathlessness. 
 
Design: Systematic review reported in accordance with the Preferred Reporting Items for Systematic 
Review and Meta-analysis (PRISMA) statement; PROSPERO Registration CRD42017055909. 
 
Data sources: Six electronic databases and grey literature were systematically searched up to 
January, 2017. Inclusion criteria: (i) empirical studies reporting data on driving simulation, on-the-
road driving tasks or driving outcomes; (ii) people with chronic pain or chronic breathlessness; and 
(iii) taking regular therapeutic opioid agonists. Critical appraisal used the National Institutes of 
Health’s quality assessment tools. 
 
Results: From 3809 records screened, three studies matched the inclusion criteria. All reported data 
on people with chronic non-malignant pain. No significant impact of regular therapeutic opioid 
agonists on people’s driving-related psychomotor skills was reported. One study reported more 
intense pain significantly worsened driving performance.  
 
Conclusions: This systematic review does not identify impaired simulated driving performance when 
people take regular therapeutic opioid agonists for symptom control, although more prospective 
studies are needed.  
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Key Statements 
 
What is already known about the topic? 
• Being able to drive is important for most adults 
• Not being able to drive is associated with worse health-related outcomes 
• Different studies, from different participant groups, using differing assessment tools, show 
conflicting results on the impact of opioids on driving-related psychomotor skills 
What this paper adds? 
• There is a paucity of studies evaluating the impact of opioid agonists on driving-related 
psychomotor skills in participants with chronic pain or chronic breathlessness  
• Stable doses of opioid agonists may pose no increased driving risk to people using them for 
long term symptom control  
• Pain may have a negative impact on people’s performance, itself more significant than 
regular therapeutic opioid agonists 
Implications for practice, theory or policy 
• There is a need to further investigate what is the impact of therapeutic opioid agonists for 
long term symptom control on people’s driving skills 
• Prospectively collected data need to focus on specific populations, opioid formulations and 
driving outcomes as regular therapeutic opioid agonists are initiated, titrated and 
maintained 
• Defining which specific groups of patients may be able to drive or not drive safely will 
contribute to informed decision making by clinicians faced with providing advice to patients 
and their families, with the potential to improve health-related outcomes 
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Introduction 
 
For many adults, driving is a key daily activity, strongly associated with personal freedom and 
independence.1 Not being able to drive impacts on one’s self-image, limits the ability to work, 
impairs independence for many basic activities and reduces overall quality of life. 1,2 Driving 
cessation is associated with social isolation 3 which has been associated with decrements in several 
health-related domains, higher risk of being admitted into long-term care facilities and higher 
mortality.4-6 Being unable to drive is associated with doubling of depressive symptoms.6-8  
 
For patients with chronic conditions requiring palliative care, being able to drive is still important. 
From a cohort of 173 people with life-limiting illnesses, 23% were current drivers and 16% still 
considered it an option.9 Almost all patients mentioned that keeping their driving licences was 
important stating reasons such as identification, hope and emergencies.9 
 
Concurrently, many people with chronic conditions live with a significant symptom burden requiring 
a range of management strategies including the use of regular therapeutic opioid agonists.10,11 
Regular therapeutic opioid agonists are currently recommended as the first line treatment for 
moderate to severe cancer pain,12 moderate to severe chronic non-malignant pain when other 
medications fail to provide relief 13 and for reducing chronic breathlessness when symptom relief is 
unattainable with optimal treatment of underlying causes.14,15 When initiated, titrated and managed 
using the best available evidence, regular therapeutic opioid agonists have been shown to be safe, 
have minimal potential for addiction and improve quality of life.15,16  
 
Despite their benefits, some studies evaluating the efficacy and safety of therapeutic opioids report  
high incidences of dizziness, sedation 17 and cognitive and psychomotor impairment,18-20 while others 
report no significant problems 21-23 A systematic review on this topic identified that most studies are 
heterogeneous and fail to report confounders, limiting the generalizability of results.24 
 
To address this gap, this systematic review is based on the best available evidence in relevant 
populations, covering pure opioid agonists. Outcomes were selected to minimise heterogeneity of 
study design or populations where possible. This study therefore investigates the effect of regular 
therapeutic opioid agonists for chronic pain or chronic breathlessness on driving safety. 
 
Opioids 
 
i) Type of Opioids  
Opioids have heterogeneous pharmacokinetic and pharmacodynamic profiles which influence 
clinical responses.25,26 For example, opioids bind with different affinities to the opioid receptors.27 
Full agonists have high affinity to opioid receptors, producing maximum clinical effect. These opioids 
do not have a ceiling effect for analgesia and the dose selected is the one that produces maximum 
clinical effect with manageable adverse events.27 Other classes of opioids (e.g. partial agonists; 
mixed agonists-antagonists) have a sub-optimal action on the opioid receptors. These classes have a 
celling effect which limits the dose escalation.27  
 
Even within opioid agonists, there are substantial differences. For example, methadone is an opioid 
agonist that also has action as an antagonist of N-methyl-D aspartate  (NMDA) receptors.28 NMDA 
receptors play an important role in memory dysfunction and cognition,29 meaning any effect 
observed on driving performance may be caused by this mechanism of action rather the its effect on 
opioid receptors. As such, within opioid class differences must be considered when evaluating 
driving performance.  
 
 5 
ii) Routes of administration and Formulations 
Oral opioids are available in two formulation types: immediate release and extended release.30 Long-
acting opioid formulations are now recommended as first-line options for prolonged therapy.31,32 
Their pharmacokinetic profiles show less fluctuations in plasma concentration, higher minimum 
plasma concentration (Cmin) and longer time with maximum concentrations (Tmax).33 This is important 
because a lower Cmax can potentially be associated with fewer adverse events 34 including sedation, 
cognitive impairment and psychomotor performance. Transdermal formulations are similar to oral 
extended release formulations because they allow a slow diffusion of the drug to the bloodstream 
which also enables steady plasma concentrations over a prolonged period.35 Other formulations (e.g. 
intravenous, intranasal, buccal, sublingual, rectal) exhibit variable pharmacokinetic characteristics 36 
and are not recommended as first line, regular therapy.  
 
iii) Opioid Agonist Dose 
Sedation is a common side effect of opioids that may impact on cognition, psychomotor 
performance and driving ability. Some longitudinal studies have suggested that high doses of opioids 
may cause cognitive impairment while low opioid doses may not.37 There is a wide therapeutic 
window for opioids in healthy individuals 38 due to genetic and acquired influences.39 While 
pharmacokinetic characteristics contribute to inter-individual differences in opioid response, 
pharmacodynamic adaptations play a crucial role in changes in opioid response longitudinally.39 For 
example, the µ-opioid receptor, the most important mediator for analgesia and sedation 27 has a 
highly dynamic pattern of expression. This receptor is over-expressed in peripheral inflammatory 
states 40 frequently associated with pain and breathlessness but under-expressed in other situations 
like chronic opioid exposure.41  
 
As such, some specific situations, rather than the opioid dose per se, need to be considered in the 
clinical setting: 
a) Dose initiation: Single-dose studies show that side-effects of opioids are accentuated when 
therapy is initiated. 42,43 Most people rapidly develop tolerance to opioid-induced sedation,44 
allowing safe driving.45 
b) Upward dose titration: Patients taking therapeutic doses of opioids may experience 
increased sedation and cognitive and psychomotor impairment following an increase in their 
regular opioid dose.18  
c) High steady state:  Opioid agonists bind to the opioid receptors in a log-linear fashion.25 As 
opioid-agonist doses increase, symptom relief improves or side effects emerge.25 After this 
point, sedation, cognitive and psychomotor impairment may persist even with stable doses.   
 
Patients taking opioids for chronic breathlessness constitute a particular case because the doses 
required to relieve this symptom are particularly low (up to 30mg/day oral morphine equivalent 
dose).46 As such and for the purpose of this work, this cut-off was used to differentiate high and low-
doses. This is important because it is currently not fully understood the effects of such small doses in 
patients-related psychomotor skills, particularly in steady state.  
 
Population who stop driving 
Amongst the elderly population, the most common reason to stop driving is impairment as a result 
of medical problems.47 This population has a higher incidence of chronic conditions 48 that reduce 
mobility and require treatment with multiple medications.49. Additionally, chronic pain or chronic 
breathlessness are often present and require symptomatic treatment and palliative approaches.50-52 
For the purpose of this work, chronic pain is defined as “ongoing or recurrent pain, lasting beyond 
the usual course of acute illness or injury or more than 3 to 6 months, ad which adversely affects the 
individual’s well-being”.53 Chronic breathlessness is defined as “breathlessness that persists despite 
optimal treatment of the underlying pathophysiology and that results in disability”.54 Understanding 
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the real effects of long-term opioids in patients’ driving-related skills is therefore challenging 
because many factors (e.g. age, chronic diseases, chronic symptoms and other medications) may 
interact to produce cognitive and psychomotor impairment.55,56 These factors need to be taken into 
account when considering any driving outcomes in this population.  
 
Measures of Driving Performance 
The current best way to evaluate driving skills is an on-the-road driving test 57 which consists of a 
100-km drive on a public highway, under regular traffic conditions. Because it is time consuming, this 
test is difficult to apply in clinical or research settings. As such, researchers have been looking for 
alternative outcome measures that could accurately predict on-road outcome.58 Driving is a task 
requiring numerous skills, including concentration over long periods of time, being able to receive 
multiple sensory stimuli, process them, make decisions and respond appropriately.59 This requires 
preserved cognitive abilities like concentration, attention, perceptual skills, insight and memory.60 
Based on this, batteries of cognitive and psychomotor tests are frequently used as quick and easy 
predictors of on-road driving performance.61. However, research indicates these tests or 
combination of tests are poor predictors of driving performance.58,62,63 In fact, a battery of five 
psychometric tests has been shown to have a total predictive value of only 33.4% to the on-the-road 
driving test.58 A good alternative to these tests is driving in a simulator because they have higher 
external validity to detect drugs’ (alcohol or illicit drugs) or sleep disorders’ detrimental 
effects on driving.64-67 There is increasing evidence driving simulators are able to predict 
driving outcomes on the road.68,69 
 
Research Questions  
Given the methodological research issues when considering the use of regular therapeutic opioid 
agonists and driving, a broad research question was developed with progressively narrower sub-
questions:  
 
Research question: Does treatment with regular therapeutic opioid agonists for long-term symptom 
control (chronic pain, chronic breathlessness) impact on driving-related psychomotor skills as 
assessed by a driving simulator or an on-road driving task? 
 
Sub-questions: 
1. Are people taking therapeutic regular opioid agonists for long-term symptom control 
(chronic pain, chronic breathlessness) able to drive safely? 
2. Do any data specifically relate to either:  
a. Prescribed extended-release or transdermal formulations? 
b. Prescribed low doses (≤30mg/day oral morphine equivalent dose) or is there a dose-
response relationship? 
c. Both a and b? 
 
Methods 
 
This systematic review is reported in accordance with the Preferred Reporting Items for Systematic 
Review and Meta-analysis (PRISMA) statement.70  
 
Design: Systematic Review  
 
Protocol and Registration  
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This systematic review protocol was registered in PROSPERO – international prospective register of 
systematic reviews (Registration Number CRD42017055909; available in 
https://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42017055909).  
 
Eligibility Criteria 
English language, peer-reivewed studies were included if they reported empirical data on: driving-
simulation, ‘real-world’ driving or driving outcomes in adults taking therapeutic opioid agonists for 
long term symptom control. Studies using opioid-agonists with a strong action on NMDA receptors 
(e.g. methadone) were excluded. By acting both on the opioid receptors and NMDA receptors, they 
have the potential to cause cognitive side effects by different mechanisms. As such it would be 
difficult to generalise results to other opioid agonists. Anaesthesia and surgical settings were 
excluded because of single dose or short term exposure, and the likelihood of exposure to  other 
centrally acting medications, surgical interventions, and invasive procedures that all could influence 
driving ability.71 Studies conducted with populations with severe renal or hepatic impairment were 
also excluded because opioid agonists are, to different extents, metabolised/excreted by these 
organs.72  
The participant / intervention / control / outcome (PICOS) for this systematic review is in Table 1.   
 
Table 1- PICO 
 
Information Sources and Search Strategy 
The following databases were systematically searched up until 15 January 2017: Medline (Ovid, 
1946-2016), PubMed (Non-Medline subset only which includes citations not yet or never-to-be 
indexed for Medline), Cochrane Library (Cochrane Database of Systematic Reviews, Cochrane 
Central Register of Controlled Trials, Database of Abstracts of Reviews of Effect), EMBASE (Ovid, 
1974-2016), Scopus and the Cumulated Index to Nursing and Allied Health Literature: CINAHL 
(ESBCOhost).  
 
 The final search strategy included two sets of terms. Set 1 was designed to include all literature 
relating to opioids, particularly the most common opioid agonists used in clinical practice. Set 2 was 
created to capture all terms related to driving-related psychomotor skills which included driving-
simulation, driving tasks and driving outcomes (e.g. accidents). Within each set, terms were 
combined using the Boolean Operator ‘OR’. Both sets were then combined using the Boolean 
P (Population) Adults (≥ 18 years) requiring opioid agonists for pain or breathlessness control 
I (Intervention) Therapeutic regular opioid agonists for chronic pain or chronic breathlessness  
      Sub-group examination of: 
I. Extended-release or transdermal formulations 
II. Low doses (≤30mg/day oral morphine equivalent dose) or dose-
response relationship 
III. Both a and b 
C (Comparison) Placebo / No intervention / Control group 
O (Outcome)  Impairment on driving-related psychomotor skills as assessed by: 
- Driving simulator 
- On-the road driving tasks 
- Driving outcomes (e.g. accidents) 
S (Setting) Hospital, community, ambulatory 
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Operator ‘AND’ (Table 2). Pain and breathlessness were not included as a separate set of terms but 
they were hand searched at a later stage from the list of retrieved articles.  
 
Before running the final search strategy, a preliminary search of Medline was conducted to identify 
suitable Medical Subject Headings (MeSH terms) and useful textwords included in titles and 
abstracts. A detailed search was then constructed in Medline (Ovid; Table 2) and translated for each 
database of interest (Appendix 1). Consultation with a specialist research librarian was undertaken 
to ensure that the search strategy was appropriate.  
 
Grey literature was searched using Google, Google Scholar, the Australian New Zealand Clinical Trials 
Registry (ANZCTR), the ClinicalTrials.gov database and the ProQuest Dissertations & Theses Database 
(PQDT). Additionally, the reference lists of relevant articles were hand searched.  
 
Table 2 - Medline search strategy: conducted in December 2016 
 
  
# Searches  
1 
analgesics, opioid/ or codeine/ or fentanyl/ or hydromorphone/ or morphine/ or 
oxycodone/ Set 1 
2 (opioid* or codeine or fentanyl or hydromorphone or morphine or oxycodone).tw. 
3 or/1-2  
4 automobile driving/ or driving under the influence/ or Accidents, Traffic/ 
Set 2 
5 
((abilit* or competen* or skill* or task* or simulation* or aptitude* or perform* or 
capacit* or capab* or function* or risk* or safe* or unsafe or impair* or danger* or 
influence or fit* or unfit or impact or advice or cessation or restrict*) adj4 driv*).tw. 
6 (automobile* or car or cars or road or traffic or accident* or crash*).tw. 
7 reaction time/ 
8 (react* adj2 time*).tw. 
9 or/4-8  
10 3 and 9  
11 Animals/ not (Human/ and Animals/)  
12 (Letter or comment or editorial or news or case reports).pt.  
13 10 not (11 or 12)  
14 limit 13 to English language  
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Study Selection 
Relevant articles were managed using Endnote X7 (Thomson Reuters, Philadelphia, PA). First, 
duplicates were removed. Subsequently, articles that did not match the eligibility criteria were 
excluded. Two authors (DF, JP) independently reviewed all titles and abstracts in order to assess 
their relevance for inclusion. Full-text papers were retrieved for all those fulfilling the inclusion 
criteria or anywhere there was equivocation using title and abstract alone. Full texts of all remaining 
relevant studies were then assessed. Specific reasons were provided for any articles excluded at this 
stage. Disagreement at all stages was resolved by discussion or recourse to a third author (DC).  
 
 
Data Extraction Process 
Data from potentially relevant studies were extracted by two authors (DF, JB). A Data Extraction 
Form was developed to collect information from potentially relevant studies. Fields included year of 
publication, journal, title, first author, country, settings, study design, time period, number of 
subjects, % men, mean age, diagnose, type of opioid agonist, dose, acute or chronic administration 
(≥7 days), route, formulation, type of test performed and outcomes. The data collection forms were 
complied with randomised controlled trials, observational studies, systematic reviews and meta-
analyses.  
 
Quality and risk of bias appraisal 
Critical appraisal of the included studies was conducted using the quality assessment tools from the 
National Institutes of Health (NIH).64 The NIH tools can accommodate a range of study designs. All 
included studies were independently rated by two researchers (DF, JB) for quality and risk of bias. 
Incongruences in rating were discussed in order to achieve a consensus.  
 
Synthesis of results 
Given the variety of study designs, a narrative synthesis was conducted based on the methods 
described by Popay et al.73 
Results 
 
Study Selection  
The initial systematic search retrieved a total of 6553 articles: MEDLINE (n=1179), PubMed (non-
Medline content only) (n=221), Embase (n=2197), CINAHL (n=64), Cochrane Database of Systematic 
Reviews (n=3), Cochrane Central Register of Controlled Trials (n=234), Database of Abstracts of 
Reviews of Effect (n=5), and Scopus (n=2650). Three more articles were found by hand search. A 
total of 3809 articles remained after removal of duplicates. After screening title and abstract, 29 
papers had full text assessed, 26 excluded, leaving three articles meeting inclusion criteria (Figure 1).   
Study Characteristics, Quality and Bias  
Of the three included studies, one was a cross-sectional study,74 one had a pre- and post-test 
design75 and one was a case-control study 76 (Table 3). All were published between 2000 and 2011. 
Two studies were conducted in the USA 75,76 and one in Norway.74 The quality of  studies was ‘good’ 
or ‘fair’ according to the NIH quality assessment tools (Tables 4). The heterogeneity in methodology 
and reporting made a meta-analysis impossible.  
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Figure 1 – PRISMA Diagram 
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Population and Setting 
All studies included participants with chronic non-malignant pain followed in outpatient pain clinics. 
Mean age in the opioid group (N=59) was 43-48 years old.74-76 For two of the studies, diagnosis in the 
opioid group (N=43) included musculoskeletal conditions (62.8%), neuropathic pain (32.6%), 
abdominal pain (2.3%) and chronic headache (2.3%). The third study 76 reported additional diagnoses 
of fibromyalgia and reflex sympathetic dystrophy but distribution of participants in each diagnostic 
group was not reported. Mean pain intensity was reported in all studies using Numerical Rating or 
Visual Analogue Scales (NRS; VAS). Menefee et al 75 reported a statistically and clinically significant 
reduction in mean pain scores between the baseline visit and the stabilization visit (mean VAS score 
at baseline = 67; mean VAS score at the stabilization visit = 53; p=0.02).75 Nilsen et al 74 reported no 
significant differences between the chronic pain group taking opioids (mean NRS score = 5.8) and 
the first control group of participants with chronic pain not taking opioids (mean NRS score = 5.5; p 
NS) over the week prior to the assessment. Additionally, pain scores did not differ significantly 
between groups at the time of the first (NRS scores = 4.8 and 4.6 respectively; p NS) and second 
driving assessments (NRS scores = 5.1 and 5.7 respectively; p NS). However, a significant difference 
in the average pain score over the preceding week was reported between the chronic pain group 
and the second control group (healthy volunteers; NRS scores = 5.6 and 0.4 respectively; p<0.05).74 
Galski et al 76 reported no significant differences in pain scores between the active (mean NRS score 
= 3.48 ± 2.4) and the control group (mean NRS score = 3.66 ± 2.5) at the time of the driving 
assessments.76 
 
Type of opioids, dose, formulations and routes reported 
All studies included only participants on regular therapeutic opioid agonists. One study included only 
short-acting opioids and two studies included only extended-release formulations as regular 
therapy.76 Nilsen et al included participants taking regular oral codeine. Menefee et al 75 included 
participants taking transdermal fentanyl only with a maximum of 3 pro re nata (PRN) tablets of 
acetaminophen 325mg/oxycodone 5mg per day during the titration period (75). Galski et al 76 
included participants taking long-acting opioids which comprised controlled-release oral morphine 
and transdermal fentanyl. PRN opioids including hydromorphone and oxycodone were allowed. 
Doses utilised in this study were not reported. Fentanyl doses ranged from 25 to 75µg/hour in the 
Menefee et al study 75 with a median dose of 50ug/hour (oral morphine daily equivalent doses: 60-
180mg, median 120mg).77 Codeine doses ranged from 120- 270mg/day in the study from Nilsen et al 
74 with a median dose of 180mg (oral morphine daily equivalent doses: 12-27mg, median 18mg).77 
 
Driving Outcomes  
Overall, studies found no significant changes in driving-related outcomes with opioid-agonists (Table 
5). 
 
Nilsen et al 74 tested the participants twice on the same day coinciding with peak and trough codeine 
blood concentrations respectively. Reaction times, steering precision and missed signs were 
analysed in rural and urban driving settings. No significant differences were found between 
participants with chronic pain taking codeine (n=20) and participants with chronic pain free of 
opioids (n=20) in any of the study measures (p>0.5; CI 95%). However, the chronic pain group (n=40) 
performed significantly worse compared with healthy controls in all study parameters (p<0.036). 
 
Menefee et al subjected participants to four different driving tasks where simple braking reaction 
time, cue reaction time, destination driving and evasive action were evaluated. For the first three 
tasks, the average of errors in breaking, steering, speed and signalling were calculated to achieve a 
final score. Evasive action was measured using the average time spent to take appropriate action in 
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three different driving situations. This study found no significant differences in driving-simulator 
performance parameters before and after fentanyl therapy (p≥0.2).75
 Table 3 – Summary of studies characteristics 
Study N Subjects N (% 
men) 
Population Mean Age 
(years) 
Design Comparison Time Period Formulation Type of 
Assessment 
Outcome Statistical 
Power 
Nilsen, 
2011 
60 (20 per 
group) 
50% Participants 
with chronic 
non-
malignant 
pain  
43.2 
codeine 
group;  
 
no 
significant 
differences 
between 
groups 
Cross-
sectional 
Oral Codeine 
(12mg-27mg 
OME/day (mean 
18mg OME/day) 
vs  
Matching Chronic 
pain participants 
not using codeine  
vs  
Matching Healthy 
Volunteers 
NA Rapid 
Release 
Driving-
Simulator 
Primary outcome: 
Reaction time 
(seconds) to traffic-
sign symbols and 
missed reactions. 
 
Secondary outcome: 
steering precision 
(pixels). 
Twenty 
subjects per 
group 
provide over 
80% power 
for detecting 
a difference 
with p < 0.05 
Menefee, 
2004 
23 26% Participants 
with non-
malignant 
pain 
47 Pre- and 
Post-test 
design 
Fentanyl TD (60-
180 mg OME/day, 
median 120mg 
OME/day); 
Participants 
tested before and 
after exposure 
before 
initiating 
drug;  
vs  
after 1 
month of 
stable dose  
Extended-
release 
Driving-
simulator 
Average of errors in 
the following tasks: 
Simple braking 
reaction time;  
Cue reaction time; 
Destination Driving. 
 
Average of time 
spent to take 
appropriate action in 
3 different driving 
scenarios (evasive 
action). 
No reference 
Galsky, 
2000 
16 opioid 
group; 327 
historical 
control 
group 
NI Participants 
with non-
malignant 
pain 
48.38 Case-
control 
study  
Opioid agonist in 
stable doses; 
vs  
Cerebral 
compromised 
participants 
previously cleared 
to drive 
NA Slow or 
extended-
release 
Driving-
simulator 
Number of errors in 
braking, steering, 
accelerating, speed 
and signalling. 
No reference 
*OME: Oral morphine equivalent 
 Table 4 - NIH Quality Assessment Tools (Critical appraisal) 
 Study 
Questions Nilsen, 2011 Menefee, 2004 Galsky, 2000 
 NIH Quality 
Assessment Tool for 
Observational 
Cohort and Cross-
Sectional Studies 
NIH Quality Assessment 
Tool for Before-After 
(Pre-Post) Studies with 
No Control Group 
NIH Quality 
Assessment of Case-
Control Studies 
1. Research question / objectives clearly stated Yes Yes Yes 
2. Study population clearly identified Yes Yes Yes 
3. Similarity between sample and population of 
interest 
Yes Yes No 
4. Application of the eligibility criteria  Yes Yes Yes 
5. High % of eligible participants enrolled or 
randomly selection of eligible participants 
No Yes Yes 
5. Sample size calculation Yes No No 
6. Exposure preceded outcome  Yes Yes Yes 
7. Definition and consistent measures of 
exposure 
Yes Yes Yes 
8. Definition and consistent measures of 
outcomes 
Yes Yes Yes 
9. For exposures that vary in amount or level, 
measurement of different levels of the exposure 
as related to the outcome (e.g., categories of 
exposure, or exposure measured as continuous 
variable) 
Yes NA NA 
10. Blinding of outcome assessors NR NR No 
11. Loss to follow up ≤ 20% (included in the 
analysis) 
Yes Yes NA 
12. Timeframe adequacy Yes NA NA 
13. Measurement of confounding variables Yes NA No 
14. Measurement of effects at a group level  NA NA NA 
Classification (Good, Fair, Poor) Good Good Fair 
 
NR: Not Reported 
NA: Not Applicable
 Table 5 - Driving Simulator Performance: Specific Outcomes 
 Simulator Measures      
 
 
 
 
Nilsen, 2011 
 CP* taking Codeine  
Group 1 
Mean (SD) 
CP* no opioids 
Group 2 
Mean (SD) 
Healthy Volunteers 
Group 3 
Mean (SD) 
P values  
(Group 1 vs 2;  
Groups 1+2 vs 3)   
Statistical Test 
Reaction Time Rural Test (choice 
reaction) b 
0.96 (0.14) 0.93 (0.11) 0.84 (0.13) P=0.53 ; P=0.026c  
 
Multiple Regression Reaction Time Urban Test (simple 
reaction) b 
0.87 (0.21) 0.88 (0.13) 0.76 (0.13) P=0.98 ; P=0.035c 
Missed Reactions Rural Test Because missed reactions in the rural condition were <1% only the results for the urban condition 
were reported 
Missed Reactions Urban Test a,b 10.20 [CI 95% (8.85-
11.69)] 
10.85 [CI 95% 
(9.45-12.39)] 
6.10  [CI 95% (5.07-
7.28)] 
P=0.19 ; P=0.001 
Steering Precision Rural Test The steering precision results were equal Poisson Regression 
Steering Precision Urban Test The steering precision results were equal 
        
 
 
 
Menefee, 
2004 
 Before fentanyl  
Mean (SD) 
On fentanyl 
Mean (SD) 
P value  
 
 
Wilcoxon Signed Rank 
Test 
Simple breaking reaction time, seconds 0.90 (0.17) 0.91 (0.18) 0.74 
Cue recognition reaction time, seconds 0.88 (0.17) 0.91 (0.23) 0.72 
In-town driving, errors made 13.2 (4.4) 13.0 (3.6) 0.20 
Highway destination driving, errors made 5.3 (2.4) 5.3 (2.8) 0.24 
Evasive action reaction time, seconds 0.90 (0.03) 0.76 (0.36) 0.29 
        
 
 
 
 
 
 
Galsky, 2000 
 CP* taking opioids CCompromised** Participants P value Analysis of Variance 
(ANOVA); 
 
Tukey’s honest significant 
differences (HSD) test: 
differences between CPP 
taking Opioids and 
CCompromised** 
Participants who passed 
the behind-the-wheel 
driving test (post hoc 
comparisons) 
Basic Acceleration % Errors 3.50 ± 6.26 7.15 ± 11.47 No significant difference 
Basic Signalling % Errors 14.63 ± 15.01 23.30 ± 20.27 No significant difference 
Basic Breaking % Errors 31.25 ± 26.22 37.66 ± 23.12 No significant difference 
Basic Steering Distance 56.19 ± 24.74 70.74 ± 20.47 No significant difference 
Evasive Action Braking Distance 39.83 ± 19.33 48.95 ± 25.95 No significant difference 
Evasive Action Braking % Valid 73.44 ± 24.95 65.17 ± 31.55 No significant difference 
Evasive Action Steering Distance 75.79 ± 39.36 69.46 ± 37.44 No significant difference 
Evasive Action Steering % Valid 43.79 ± 32.09 40.86 ± 29.67 No significant difference 
Threat Recognition Braking Distance 113.74 ± 22.13 125.95 ± 34.22 No significant difference 
Threat Recognition Braking % Valid 82.50 ± 29.10 60.47 ± 33.63 P<0.05 
Threat Recognition Steering Distance 102.88 ± 32.72 117.99 ± 25.10 No significant difference 
Threat Recognition Steering % Valid 75.00 ± 28.75 78.59 ± 27.51 No significant difference 
* CP: Chronic-pain participants  ** CCompromised: Cerebral compromised  
a Mean numbers of long reaction times(>3.95 s) for each subject (out of 104 possible reaction times for each subject). 
b No significant differences were found between high (peak) and low (trough) blood concentration levels (p>0.05).c Age-adjusted P values and differences  
 Galski et al found no significant differences in driving parameters (number of errors in braking, 
steering, accelerating, speed and signalling) between participants with chronic pain taking opioid-
agonists and cerebrally compromised participants accessed as fit to drive after an on-the-road 
driving test.76  
 
Discussion 
 
Summary of Evidence 
This research highlights the paucity of studies evaluating the impact of regular opioid agonists in 
driving-related psychomotor skills of participants with chronic pain or breathlessness, the most 
common symptoms requiring the use of therapeutic opioids and other palliative interventions. All 
three studies included in this review report data on participants with chronic non-malignant pain 
which demonstrates the lack of evidence available for participants with chronic cancer pain or 
chronic breathlessness. Additionally, only one study provided a power calculation.74 Nevertheless, all 
three studies showed no negative impact on participants’ driving-related skills when compared to 
control groups which suggests that participants with chronic non-malignant pain on stable doses of 
regular therapeutic opioid agonists can drive safely.  
 
Are participants on therapeutic, regular opioid agonists for chronic pain or chronic breathlessness 
able to drive safely? 
All three studies filled the inclusion criteria for this question. All studies reported similar results: for 
participants with chronic non-malignant pain, regular therapeutic opioid-agonists did not 
significantly impair driving-related psychomotor skills.74-76 This is line with results from a previous 
review that examined the effects of opioids on opioid-dependent/tolerant participants’ driving-
related skills that found no association between opioids and changes in driving-related outcomes.45 
These results are also similar to those published in a previous observational work showing no effect 
of opioids on the  driving ability of participants with chronic pain.23 Byas-Smith et al evaluated two 
groups of participants with chronic pain through a community-driving task and an obstacle-course 
task. The first group was not taking opioids and the second group was taking stable doses of opioids 
for chronic pain. No significant differences were found between groups in all specific measures of 
driving ability, even though different types of opioids were included.23 Importantly, no studies 
reporting data on participants with chronic cancer pain or chronic breathlessness filled the inclusion 
criteria for this review which highlights an important research gap.  
 
Extended-release or transdermal formulations 
The inclusion criteria for this question encompassed participants taking regular, extended-release 
oral or transdermal opioid-agonists which are frequently prescribed for long-term therapy.32 Two 
studies were included in this group: one using transdermal fentanyl;75 and other several types of 
strong opioid agonists in controlled-release formulations.76 Controlled-release opioid-agonists 
showed no significant impact on driving-simulator performance even with the addition of occasional 
PRN opioids for incidental pain. Based on the current available evidence, it is difficult to know if the 
use of extended-release opioids agonists represents any advantage compared with immediate-
release preparations when considering participants driving performance. However, one study 
comparing the two types of formulations has found that participants reported statistically significant 
more tiredness after a titration period with the immediate-release formulation 78 which could 
potentially cause a detrimental impact on participants’ driving-related skills.76 Studies comparing 
these two types of formulations should then be developed to bring light into this issue.  
 
Low doses (dose-response relationship) 
 Nilsen et al 74 was the only study using low doses of opioids (median dose 18mg oral morphine 
equivalent dose). This dose range is effective in reducing the sensation of breathlessness in most 
participants with chronic breathlessness 15 and its importance should be highlighted. Importantly, 
these findings are similar to the ones from Menefee et al 75 (median oral morphine equivalent dose 
120mg) and Galski et al 76 (unknown doses). One theory is based on the fact that neuroadaptation 
quickly develops following exposure to an unchanged dose of an opioid agonist.61 This corroborates 
findings from previous studies showing that stable doses of opioids fail to produce cognitive 
impairment while therapy initiation and up-titration produce significant cognitive and psychomotor 
impairment.18,61 However, epidemiological data suggest that very low doses of opioids (defined as 
doses <20 mg of oral morphine equivalent a day) may be safer than higher doses when it comes to 
performance on the road 79 even when controlling for potential confounders like age, 
hospitalizations, other medication use and number of emergency department visits in the previous 
year. Further research should also take this factor into consideration.  
 
Prescribed extended-release, low dose opioid agonists 
No study was available evaluating the effects of therapeutic, regular, low-dose, extended release 
opioids for pain or breathlessness on driving-related psychomotor performance. As such, the answer 
to this question remains unknown. Further research should focus on examining the effects of low-
dose, extended-release opioid formulations in participants’ driving ability. 
 
Impact of pain and breathlessness 
Pain and breathlessness are often reported by participants suffering from chronic diseases like 
cancer, degenerative joint disease, and chronic cardiorespiratory diseases amongst others.50,51 In 
fact, participants that are suffering from pain are more likely to report breathlessness and 
participants with breathlessness have also a higher prevalence of pain.80 Additionally, pain and 
breathlessness commonly emerge and subside together which highlights the association between 
the two symptoms.80 One explanation is that both symptoms share common neural pathways 
especially in the limbic region.81 Another important idea is that both pain and breathlessness may be 
a reflection of the same underlying disease process. Whatever the extent of influence of these 
factors, these symptoms commonly occur in similar populations which motivated its inclusion 
together in this review.  
 
An interesting finding from the only a priori adequately powered study in this review 74 is that 
participants with chronic pain (taking and not taking opioids) performed significantly worse than 
healthy volunteers after adjusting for age, gender, education, driving experience, personality traits, 
emotional stability and extraversion. This corroborates previous findings suggesting that 
uncontrolled pain is a stronger influence on cognitive and psychomotor performance than 
prescribed opioids.82,83 Importantly, the difference in mean pain scores reported between the 
chronic non-malignant pain group and the healthy volunteer group was not only statistically 
significant but also clinically significant (pain NRS mean score 5.6 and 0.4 respectively).84 Although no 
studies were found for participants with breathlessness, there is evidence suggesting that an 
increase in the intensity of breathlessness correlates with worsening driving-related 
neuropsychological performance skills.85 These studies highlight that symptom intensity may 
influence driving performance and should be taken into account as potential confounders when 
analysing the impact of opioids in populations with chronic pain or chronic breathlessness. 
 
Strengths 
This systematic review was conducted in line with the methodology proposed by the PRISMA 
Statement.70 This is the first systematic review assessing opioids and driving-related psychomotor 
skills with a focus on population, intervention and outcomes. The selection criteria were carefully 
 thought to include: (i) a representative population of people with chronic conditions, (ii) the most 
common types of prescribed opioids selected based on current pharmacologic knowledge (iii) the 
most robust outcome measures. It is also important to highlight that the simulators used in the 
studies included in this systematic review have been previously validated for on-road driving.68,69 
This approach prevented the inclusion of a heterogeneous group of studies whose results would not 
be generalisable.   
 
Limitations 
Only three studies were included in this review as a result of the selection criteria applied. This is 
regarded by the authors as both a strength and a limitation. On the one hand, the population, 
opioids and outcomes selected are relatively homogeneous which would allow the generalisability of 
results to this group of participants. On the other hand, the scarcity of studies available means the 
conclusions cannot be definitive. This systematic review only included articles published in English 
which may have increased the risk of selection bias. Also, given the heterogeneity of study designs, a 
meta-analysis could not be performed.  
 
Recommendations for future research  
Currently there is a lack of studies assessing the impact of therapeutic opioid-agonists in people’s 
driving-related skills. All the studies included in this systematic review selected a population of 
participants with chronic non-malignant pain and the results obtained may not be generalizable for 
participants with chronic malignant pain or chronic breathlessness. However, it is important to note 
that chronic pain is a common feature of non-malignant life-limiting diseases and the results of this 
work are important for this population.86 Nonetheless, future research should also focus on 
populations with chronic malignant pain and chronic breathlessness.  
 
The impact of oral extended-release and TD formulations during the titration phase on cognitive and 
psychomotor skills is unknown, although studies in other populations suggest they may have fewer 
adverse events.34,78 Another important issue to explore in future research is the true impact of 
different intensities of pain/breathlessness in driving outcomes as they might be important 
predictors of poorer driving performances.  
 
Clinical implications  
Although opioids are currently recommended as the first line treatment for moderate to severe 
pain, many clinicians remain reluctant to use them.87 Fear of side effects is one of the top concerns 
identified by clinicians.87,88 One problem is that clinicians may withhold or withdraw opioid therapy 
from people who could potentially benefit from this therapy. Additionally, clinicians’ beliefs and a 
poor clinician-patient relationship have been shown to decrease adherence to taking analgesics as 
prescribed.89,90 
 
The studies included in this review suggest that participants with chronic non-malignant pain are 
able to drive safely while taking regular, stable doses of a therapeutic opioid agonist. One important 
factor to take into consideration is that uncontrolled symptoms like pain and breathlessness may 
contribute to worsen driving-related psychomotor skills and performance on the road, to a greater 
extent than opioids.74,82  
Conclusions 
This systematic review examined the literature about driving-related psychomotor performance of 
people with chronic pain or chronic breathlessness taking opioid agonists. Despite the evidence 
supporting the use of opioids for symptom reduction in these populations, their effects on driving 
need further exploration. From the limited available studies, for people with chronic non-malignant 
pain, stable doses of therapeutic opioid agonists do not seem to cause any significant changes in 
 driving-related psychomotor performance.  More intense chronic pain may have a significant effect 
on driving skills and should be carefully monitored and controlled. Clinicians are recommended to 
use their best clinical judgement to advise patients to drive or not to drive based not only on the 
regular therapeutic opioid agonist prescribed but also on their comorbidities, symptoms and pre-
morbid driving abilities. 
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